Dr. Mark Kiel

Dr. Mark Kiel, Chief Science Officer and Founder at Genomenon, discusses how AI is revolutionizing genomic research and precision medicine. He explains the value of clinical literature as a source of real-world data for drug development and diagnostics. Mark highlights challenges in converting this data into actionable insights and introduces advanced AI techniques for prioritizing research. He emphasizes the importance of human curation in validating AI outputs and envisions a future where automated tasks streamline processes, especially for rare diseases.